Loading clinical trials...

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) | Clinical Trials | Clareo Health

UNKNOWNPHASE2/PHASE3

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

NCT02101957•University Hospital, Angers

Summary

The purpose of this study is to evaluate the effect of cysteamine in patients with symptomatic Huntington's disease by comparing two groups of patients (cysteamine vs placebo) on the results of the Unified Huntington's Disease Rating Scale (UHDRS, Huntington study group 1996).

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinically disease-registered for at least one year, leading to consult (abnormal movements, neuropsychiatric disorders, neuropsychological impairment).
•Unified Huntington's Disease Rating Scale motor ≥ 5
•Total Functional Capacity \> 10 (≥ 11)
•Huntington Disease diagnosed with abnormal number of CAG repeats: 38 \< nucleotide expansion (CAG)
•Age between 18 and 65
•Voluntarily Patient Consent
•Patients willing and able to take oral medications, and comply with the specific procedures of the study

Exclusion Criteria

•Severe cognitive impairment or neuropsychiatric troubles.
•No drug compliance to previous treatment.
•Patients with contra indication to the realization of imaging studies (including claustrophobia ) .
•Patients who have not given their written and informed consent signed .
•No national health insurance affiliation
•Private patients of their liberty by judicial or administrative decision, or patients under supervision.
•Pregnant women ( pregnancy test will be carried out systematically for women at risk) or lactating .
•Women who could become pregnant during the study period and with no contraception.
•Patients who have developed hypersensitivity to cysteamine or penicillamine ( against indication of cysteamine ) .
•Brain Damage intercurrent MRI. Brain morphological abnormalities , other than those characteristic of the disease .
+5 more criteria

Locations (1)

CHU Angers

Angers, France

Key Dates

Start Date

October 1, 2010

Primary Completion Date

July 1, 2015

Last Updated

April 2, 2014

Enrollment

ACTUAL participants

Conditions

Huntington's Disease

Interventions

RP103

DRUG

Placebo

DRUG

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

NCT02855476

Huntington's Disease

View study

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

NCT04120493

Huntington's Disease

View study

COMPLETEDPHASE2

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 2, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Inclusion Criteria

Exclusion Criteria

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease